the median
follow-up was 33 months. The 3-year PFS and BRFS was 85.2% and 82%,
respectively. The factors associated with a worst PFS at the univariate
analysis (UVA) were: high Gleason score, pT≥3, esRT,
concomitant hormone therapy (HT), and pelvic RT. In particular, aRT and sRT
reported a significantly higher 3-year PFS compared to esRT at the UVA (93%,
85.4%, and 74.1%; p=0.000). Nevertheless, at the multivariate analysis (MVA)
only Gleason score, pT and concomitant HT remains significantly correlated with
PFS. Treatment of the relapse was: HT in 43% cases, stereotactic body
radiotherapy (SBRT) in 43% patients, and HT+SBRT in 14% patients. At the last
follow-up 8 patients deceased since, only two of which by PCa progression.
Grade 1-2 GU
toxicity during RT was: urgency (36%), dysuria (23%), increased urinary
frequency (12.1%), and urinary retention (11.8%). Nevertheless, the majority of
symptoms were present at the baseline. Grade 3 severe toxicity was represented
by 10 (3.2%) cases of incontinence and 3 (1%) cases of urgency. The incidence
of any-grade RT-related GU toxicity was significantly higher in the aRT group
than the salvage group (esRT + sRT) (83.8% versus 64.5%). When comparing the
incidence of any-grade RT-related GU toxicity in the aRT, esRT, and sRT groups
we observed a significant correlation favoring sRT, over esRT, and aRT.